# **Special Issue**

# Effects of Pharmaceutical Intervention on Cardiovascular Risk

# Message from the Guest Editors

The current approach to the prevention of cardiovascular diseases includes the promotion a healthy and physically active lifestyle as well as the administration of drugs for treating cardiovascular risk factors such as hypertension, hypercholesterolemia, or diabetes. Risk factors are often poorly treated and therapeutic goals are often disregarded, even in patients considered to be at high cardiovascular risk. There is, therefore, a need to develop new drugs and optimize the use of medications currently available. At the same time, it is necessary to develop the rapeutic strategies suited to the patient's risk profile, with the aim of pursuing an increasingly personalized approach, avoiding overtreatments, and minimizing drug-related side effects. This Special Issue welcomes manuscripts focused on (1) investigating the effects of new drugs and new treatment strategies on cardiovascular risk factors; (2) optimizing the pharmacological management of patients belonging to different risk categories; and (3) assessing patients' adherence to primary prevention drugs and studying strategies for improving adherence to treatments.

## **Guest Editors**

Dr. Giuseppe Marazzi

Cardiology Rehabilitation Unit, IRCCS San Raffaele, 00163 Rome, Italy

## Prof. Dr. Giuseppe Caminiti

- 1. Department of Human Science and Promotion of Quality of Life, San Raffaele Open University, 00163 Rome, Italy
- 2. Cardiovascular Unit, San Raffaele IRCCS, 00163 Rome, Italy

## Deadline for manuscript submissions

28 February 2025



Journal of
Cardiovascular
Development and
Disease

an Open Access Journal by MDPI

Impact Factor 2.4
CiteScore 2.6
Indexed in PubMed



## mdpi.com/si/213155

Journal of Cardiovascular Development and Disease MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 jcdd@mdpi.com

mdpi.com/journal/ jcdd





# Journal of Cardiovascular Development and Disease

an Open Access Journal by MDPI

Impact Factor 2.4 CiteScore 2.6 Indexed in PubMed





# Message from the Editor-in-Chief

### Editor-in-Chief

Prof. Dr. Thomas Brand

National Heart & Lung Institute, Imperial College London, South Kensington Campus, London SW7 2AZ, UK

## **Author Benefits**

# **High Visibility:**

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

### Journal Rank:

JCR - Q2 (Cardiac and Cardiovascular Systems) / CiteScore - Q2 (General Pharmacology, Toxicology and Pharmaceutics)

# **Rapid Publication:**

manuscripts are peer-reviewed and a first decision is provided to authors approximately 22.9 days after submission; acceptance to publication is undertaken in 2.6 days (median values for papers published in this journal in the first half of 2024).

